Mr Wilson’s interest rate outlook is central to his broader call. Falling energy prices, fading tariff-related inflation and ...
Market Index on MSN
Why CSL is rallying like a growth stock again
CSL is up 35.5% since early June, clearing its 50-day moving average for the first time in nearly a year. Is the biotech ...
The parent of bankESB and TruNorth Bank will end its 157-year history as a depositor-owned institution, in part to fund the ...
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.
The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing ...
These stocks have jumped in the double- and triple-digits.
Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...
Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with ...
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...
The stock was up 39% to $2.25 in late Tuesday morning trading. The shares are now down less than 1% in the past 52 weeks. Farokhzad, who is also the biotechnology company's chair, made the unsolicited ...
Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results